ProCE Banner Activity

My Thoughts on the Current Standard of Care for Newly Diagnosed Myeloma

Clinical Thought
Are you up to date on the latest information on frontline induction, consolidation, and maintenance regimens for patients with newly diagnosed myeloma?

Released: August 09, 2019

Expiration: August 07, 2020

No longer available for credit.

Share

Faculty

Elisabet E. Manasanch

Elisabet E. Manasanch, MD

Leader, Early Myeloma Program
Director, Myeloma Tissue Bank
Tenured Associate Professor
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Amgen, Inc.

Celgene

Janssen administered by Scientific Affairs

Oncopeptides

Faculty Disclosure

Primary Author

Elisabet E. Manasanch, MD

Leader, Early Myeloma Program
Director, Myeloma Tissue Bank
Tenured Associate Professor
University of Texas MD Anderson Cancer Center
Houston, Texas

Elisabet E. Manasanch, MD, has disclosed that she has received consulting fees from Celgene, Janssen, and Sanofi and funds for research support from Merck, Quest Diagnostics and Sanofi.